Yaniv Heled

Yaniv Heled is a national expert on the legal and ethical aspects of biomedical technologies. He has published over 20 academic articles and book chapters on the regulation of pharmaceutical markets, stem cell research, human reproductive tissue, and genetic sequencing and testing, among others. Most recently, Professor Heled co-authored “A Theory of Genetic Dimensions in the Law,” which presents an innovative framework for assisting judges and policymakers in addressing complex legal issues involving genetic science and technology.

Professor Heled’s current research projects examine the legal treatment of a novel statistical tool for assessing genetic risk—polygenic risk scores—in the context of human reproduction, including how judges and policymakers should approach issues involving this new technology. In another project, Professor Heled and co-authors examine the use of non-collegial and aggressive language in Supreme Court opinions and are developing an AI tool for identifying and quantifying such language.

In addition to his wide-ranging scholarship, Professor Heled is active in various policymaking efforts in the areas of pharmaceutical regulation, access to medicines, and regulation of reproductive technologies. He has authored and joined numerous amicus briefs, administrative agency comments, and white papers on matters related to these areas, and he regularly provides advice to not-for-profits and policymakers.

Professor Heled is on the faculty of Georgia State University’s Center for Law, Health & Society, which runs the top-ranked health law program in the United States and of the Georgia State University Center for Intellectual Property Law, of which he was the inaugural director. He teaches Patent Law, Family Law, Legislation & Regulation, Biotechnology Law, and Mental Health Law.

Prior to joining Georgia State Law, Professor Heled practiced intellectual property law with Goodwin Procter LLP in New York. He earned a J.S.D. from Columbia University School of Law. His doctoral dissertation focused on the regulation of novel biomedical technologies. In addition, Professor Heled holds an LL.M. from Columbia, where he was a Harlan Fiske Stone Scholar, and an LL.B. and undergraduate Diploma in Biology, magna cum laude, from Tel Aviv University.